Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 13/20 | 0.49 |
| ▸ | IL2 | P60568 | 1/20 | 0.44 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.41 |
| ▸ | CCNK | O75909 | 1/20 | 0.41 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17273439 | 0.92 | ALK (0.49) | ALKIL2MAP4K1MAPK1WNT3A | |
| SCHEMBL17273325 | 0.90 | ALK (0.53) | ALKIL2MAP4K1MAPK1WNT3A | |
| SCHEMBL17273338 | 0.89 | ALK (0.52) | ALKIL2MAP4K1MAPK1NEK1 | |
| SCHEMBL17273445 | 0.89 | MAPK1 (0.52) | ALKMAP4K1MAPK1 | |
| SCHEMBL15555576 | 0.88 | ALK (0.46) | ALKIL2MAP4K1WNT3ARET | |
| SCHEMBL17273308 | 0.88 | ALK (0.51) | ALKIL2MAP4K1MAPK1WNT3A | |
| SCHEMBL15557128 | 0.83 | ALK (0.56) | ALKIL2MAP4K1 | |
| SCHEMBL17273493 | 0.83 | ALK (0.59) | ALKMAPK1GPR119 | |
| SCHEMBL17273261 | 0.82 | ALK (0.59) | ALKMAPK1GPR119 | |
| SCHEMBL17273448 | 0.81 | JAK2 (0.42) | WNT3AGPR119RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9353107-B2 | 3-(pyrazolyl)-1H-pyrrolo[2,3-b]pyridine derivatives as kinase inhibitors | AURIGENE DISCOVERY TECHNOLOGIES LIMITED (IN) | 2016-05-31 | — | — | US | disclosed |
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | Um Pharmauji Sdn. Bhd. (MY) | 2015-11-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150336949-A1 | 3-(Pyrazolyl)-1H-Pyrrolo[2,3-b]Pyridine Derivatives as Kinase Inhibitors | MAP3K3, MAP3K1, MAP3K6 | ALK 408/4885IL2 3532/4885MAP4K1 27/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.